Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | GMNN | O75496 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SHBG | P04278 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 2/20 | 0.32 |
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 2/20 | 0.32 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7330707 | 0.79 | TP53 (0.47) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL3586116 | 0.74 | TP53 (0.50) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL12879212 | 0.73 | TP53 (0.54) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL9896547 | 0.73 | TP53 (0.54) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL2732081 | 0.73 | TP53 (0.54) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL7895924 | 0.72 | TP53 (0.44) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL23270700 | 0.72 | TP53 (1.00) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL5228082 | 0.72 | TP53 (1.00) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL133228 | 0.72 | TP53 (1.00) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL4079339 | 0.72 | TP53 (1.00) | TP53KDM4EGMNNLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10098962-B2 | Glycosaminoglycan derivative and method for producing same | SEIKAGAKU CORPORATION (JP) | 2018-10-16 | — | — | US | disclosed |
| US-20160151506-A1 | GLYCOSAMINOGLYCAN DERIVATIVE AND METHOD FOR PRODUCING SAME | SEIKAGAKU CORPORATION (JP) | 2016-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160151506-A1 | GLYCOSAMINOGLYCAN DERIVATIVE AND METHOD FOR PRODUCING SAME | CSGALNACT1, CD44, GUSB | TP53 4405/4885KDM4E 3597/4885GMNN 1051/4885 |
| US-10098962-B2 | Glycosaminoglycan derivative and method for producing same | CSGALNACT1, CD44, GUSB | TP53 4405/4885KDM4E 3597/4885GMNN 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.